Non-Invasive Brain Tumor Focused Ultrasound Ablation System TumorSonic Receives FDA Approval: Ablating Brain Tumors Without Craniotomy

Non-Invasive Brain Tumor Focused Ultrasound Ablation System TumorSonic Receives FDA Approval: Ablating Brain Tumors Without Craniotomy

TumorSonic, a brain tumor focused ultrasound ablation system jointly developed by InSightec and Mayo Clinic, received FDA approval on August 25, 2030. The system uses high-intensity focused ultrasound from outside the skull to precisely ablate brain tumor tissue without cutting the scalp or skull, marking the entry of brain tumor treatment into the non-invasive era.

TumorSonic works similarly to a magnifying glass focusing sunlight to ignite paper. The system features a hemispherical array of 1,024 ultrasound transducers surrounding the patient's head, each independently controlling the phase and intensity of its emitted ultrasound waves. Through precise phase control, all ultrasound waves converge at the intracranial tumor location, producing temperatures of 60-80 degrees C that cause tumor tissue to coagulate and necrose.

In Phase III clinical trials, TumorSonic successfully ablated 92% of targeted tumors, with an average procedure time of 45 minutes. Compared to traditional craniotomy, TumorSonic reduced the complication rate from 18% to 3% and shortened hospital stays from an average of 7 days to 1 day.

Mayo Clinic neurosurgery chief Robert Spinner said: "TumorSonic's greatest advantage is being completely non-invasive. Patients remain conscious during treatment and can be discharged the same day. This is especially important for elderly and frail patients."

The system's key technical challenge is phase distortion when ultrasound passes through the skull. TumorSonic uses "adaptive phase correction" technology, obtaining the skull's 3D density distribution through CT scans and calculating phase compensation for each transducer to ensure precise ultrasound focusing.

TumorSonic is currently approved for treating benign meningiomas and metastatic brain tumors smaller than 3 centimeters in diameter. InSightec plans to apply for expansion to malignant glioma treatment in 2031.

A single treatment with the system costs approximately $45,000, comparable to the total cost of traditional craniotomy, but with significantly reduced patient recovery time.